Among those taking GLP-1 medications for weight loss, exercise rates are decreasing, according to new research.
The study, set to be presented at ENDO 2026 (the Endocrine Society's annual meeting) in Chicago this week, found that adults with obesity who lost weight with a GLP-1, such as Ozempic or Wegovy, "significantly reduced" their physical activity.
In an Endocrine Society press release, study lead Sajana Maharjan, MD, of HSHS St. John's Hospital in Springfield, Illinois, noted that GLP-1 drugs like semaglutide, liraglutide, dulaglutide and tirzepatide reduce both fat and lean muscle mass.
'Wild West' Peptide Craze Surges Beyond Glp-1s As Fda Faces Pressure To Ease Access
This means physical activity is "essential for preserving strength and long-term health," she said.
The study, set to be presented at ENDO 2026 (the Endocrine Society's annual meeting) in Chicago this week, found that adults with obesity who lost weight with a GLP-1, such as Ozempic or Wegovy, "significantly reduced" their physical activity.
In an Endocrine Society press release, study lead Sajana Maharjan, MD, of HSHS St. John's Hospital in Springfield, Illinois, noted that GLP-1 drugs like semaglutide, liraglutide, dulaglutide and tirzepatide reduce both fat and lean muscle mass.
'Wild West' Peptide Craze Surges Beyond Glp-1s As Fda Faces Pressure To Ease Access
This means physical activity is "essential for preserving strength and long-term health," she said.
5 months ago
